Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBSNASDAQ:RIGLNASDAQ:SGMONASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$6.63-5.2%$6.24$4.02▼$15.10$379.40M2.091.72 million shs1.00 million shsRIGLRigel Pharmaceuticals$18.84-0.5%$19.52$7.70▼$29.82$338.33M1.26208,078 shs234,110 shsSGMOSangamo Therapeutics$0.51-2.9%$0.54$0.31▼$3.18$122.86M1.239.00 million shs2.53 million shsVSTMVerastem$4.69-2.3%$6.32$2.10▼$9.10$263.76M0.711.26 million shs2.17 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions-5.15%+3.92%-0.15%+55.45%-16.39%RIGLRigel Pharmaceuticals-0.40%+0.59%-12.33%+15.09%+142.16%SGMOSangamo Therapeutics-4.51%-5.45%-3.43%-18.48%+58.70%VSTMVerastem-1.47%+13.01%-26.95%+1.08%+71.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEBSEmergent Biosolutions4.2954 of 5 stars3.51.00.04.62.12.51.3RIGLRigel Pharmaceuticals2.3981 of 5 stars3.20.00.00.00.01.73.1SGMOSangamo Therapeutics2.7187 of 5 stars3.34.00.00.02.40.80.6VSTMVerastem2.6166 of 5 stars3.53.00.00.00.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent Biosolutions 3.00Buy$14.33116.19% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4093.21% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50779.25% UpsideVSTMVerastem 3.00Buy$13.38185.18% UpsideCurrent Analyst Ratings BreakdownLatest SGMO, RIGL, EBS, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.006/24/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/14/2025SGMOSangamo TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent Biosolutions$930.30M0.39$1.82 per share3.64$8.91 per share0.74RIGLRigel Pharmaceuticals$179.28M1.88$1.07 per share17.55$0.19 per share99.16SGMOSangamo Therapeutics$57.80M2.06N/AN/A$0.11 per share4.65VSTMVerastem$10M25.77N/AN/A($0.65) per share-7.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent Biosolutions-$190.60M-$2.71N/A3.20N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$2.079.1017.94N/A18.31%-655.26%24.47%8/5/2025 (Estimated)SGMOSangamo Therapeutics-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)Latest SGMO, RIGL, EBS, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025EBSEmergent Biosolutions$0.21N/AN/AN/A$148.55 millionN/A8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.42N/AN/AN/A$64.58 millionN/A8/5/2025Q2 2025SGMOSangamo Therapeutics-$0.07N/AN/AN/A$31.68 millionN/A5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million5/7/2025Q1 2025EBSEmergent Biosolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BiosolutionsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent Biosolutions1.206.323.51RIGLRigel Pharmaceuticals2.422.202.13SGMOSangamo TherapeuticsN/A0.760.76VSTMVerastemN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent Biosolutions78.40%RIGLRigel Pharmaceuticals66.23%SGMOSangamo Therapeutics56.93%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipEBSEmergent Biosolutions1.20%RIGLRigel Pharmaceuticals9.04%SGMOSangamo Therapeutics4.10%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent Biosolutions2,42054.28 million52.54 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.26 millionOptionableSGMOSangamo Therapeutics480233.17 million223.61 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableSGMO, RIGL, EBS, and VSTM HeadlinesRecent News About These CompaniesVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2 hours ago | businesswire.comBTIG Remains a Buy on Verastem (VSTM)July 4, 2025 | theglobeandmail.comVerastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer TreatmentJuly 4, 2025 | tipranks.comAnalysts Set Verastem, Inc. (NASDAQ:VSTM) Target Price at $13.38July 1, 2025 | americanbankingnews.comVerastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian CancerJune 30, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from BrokeragesJune 28, 2025 | marketbeat.comCantor Fitzgerald Reduces Earnings Estimates for VerastemJune 28, 2025 | americanbankingnews.comVerastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related CancersJune 26, 2025 | seekingalpha.comFY2025 EPS Estimates for Verastem Cut by Cantor FitzgeraldJune 26, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - MorningstarJune 26, 2025 | morningstar.comMRoyal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceJune 25, 2025 | marketbeat.comInsider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)June 24, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 SharesJune 24, 2025 | marketbeat.comDan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) StockJune 24, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid TumorsJune 24, 2025 | businesswire.comVerastem’s SWOT analysis: biotech stock poised for growth amid challengesJune 15, 2025 | investing.comVerastem reports promising cancer drug trial resultsJune 3, 2025 | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 3, 2025 | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3, 2025 | tipranks.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2, 2025 | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGMO, RIGL, EBS, and VSTM Company DescriptionsEmergent Biosolutions NYSE:EBS$6.63 -0.36 (-5.15%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$6.62 -0.01 (-0.23%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Rigel Pharmaceuticals NASDAQ:RIGL$18.84 -0.09 (-0.48%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$18.84 +0.00 (+0.03%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Sangamo Therapeutics NASDAQ:SGMO$0.51 -0.02 (-2.87%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.52 +0.01 (+2.58%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Verastem NASDAQ:VSTM$4.69 -0.11 (-2.29%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$4.75 +0.06 (+1.28%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
